Profile
Andreas Muhs worked as the Chief Scientific Officer at AC Immune SA from 2005 to 2018.
Prior to that, he worked as the Director of Pharmacology & Histology at Cardion GmbH and as a Principal at ViaCell, Inc. Dr. Muhs holds a doctorate degree from Heinrich-Heine-Universität Düsseldorf.
Former positions of Andreas Muhs
| Companies | Position | End |
|---|---|---|
| AC IMMUNE SA | Chief Tech/Sci/R&D Officer | 2018-10-21 |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Corporate Officer/Principal | - |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Andreas Muhs
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Private companies | 2 |
|---|---|
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
- Stock Market
- Insiders
- Andreas Muhs
